comparison of effect of magnesium sulphate as an add-on therapy by different routes administration during acute exacerbation of chronic obstructive pulmonary disease

Comparing the effect of intravenous and nebulised magnesium sulphate as an adjunctive therapy during acute exacerbation of chronic obstructive pulmonary disease, A randomized control trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075401

Enrollment

112

Registered

2024-10-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J99- Respiratory disorders in diseasesclassified elsewhere

Interventions

Intervention1: intravenous infusion of magnesium sulphate: intravenous infusion of 2 gm magnesium sulphate over 20 minutes as a single dose at presentation along with standard therapy during acute exa

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of chronic obstructive pulmonary disease experiencing a moderate acute exacerbation according to the ROME proposal

Exclusion criteria

Exclusion criteria: Patients requiring immediate endotracheal intubation on arriving at the emergency medicine department. Patients with severe symptoms like breathlessness who are unable to blow into the PEFR device. Patients with altered sensorium or reduced levels of consciousness unable to blow in the PEFR device. Patients in shock with systolic blood pressure less than 100 mmhg Patients with dyselectrolytemia contraindicating the use of magnesium sulphate like hyperkalaemia and hypocalcaemia Patients with renal failure and heart block.

Design outcomes

Primary

Measure	Time frame
1.Assessment of improvement in the peak expiratory flow rate, blood gas analysis results and vital signs including heart rate, respiratory rate and oxygen saturation among participants in the study group.Timepoint: At presentation and at 60 minutes after presentation.	—

Secondary

Measure	Time frame
2. To monitor the symptomatic relief based on CAT score and assess the need for ICU admission, duration of hospital stay, need for invasive or non-invasive mechanical ventilation along with q SOFA score and CURB-65 score in these patients so as to determine the mortality and morbidity among the participants from the study groupTimepoint: at presentation and 60 minutes after presentation.	—

Countries

India

Contacts

Public ContactDr Shilpa Bawankule

Datta Meghe Institute of Higher Education and Research

drshilpagaidhane@gmail.com9673288822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026